<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625559</url>
  </required_header>
  <id_info>
    <org_study_id>CHA_CTP_0903</org_study_id>
    <nct_id>NCT01625559</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)</brief_title>
  <official_title>A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHABiotech CO., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHABiotech CO., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of RPE cellular therapy in patients with SMD&#xD;
           Group&#xD;
&#xD;
        -  When-MA09-hRPE cell transplantation to evaluate the safety of surgical procedures.&#xD;
&#xD;
        -  In future studies intended to assess the number of transplanted hRPE cells.&#xD;
&#xD;
        -  In the past, MA09-hRPE cell therapy used in the study was to evaluate the validity of&#xD;
           the potential.&#xD;
&#xD;
        -  Homologous retinal pigment epithelial cells derived from embryonic stem cells, future&#xD;
           studies of drugs that are used in representing the potential validity to evaluate the&#xD;
           optimal dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerance of transplantation</measure>
    <time_frame>18 months</time_frame>
    <description>The transplantation of hESC-derived RPE cells MA09-hRPE will be considered safe and tolerated in the absence of:&#xD;
Any grade 2 (NCI grading system) or greater adverse event related to the cell product&#xD;
Any evidence that the cells are contaminated with an infectious agent&#xD;
Any evidence that the cells show tumorigenic potential</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of successful engraftment</measure>
    <time_frame>18 months</time_frame>
    <description>Evidence of successful engraftmentEvidence of successful engraftment will consist of:&#xD;
Structural evidence (OCT imaging, fluorescein angiography, autofluorescense photography, slit-lamp examination with fundus photography) that cells have been implanted in the correct location Electroretinographic evidence (mfERG) showing enhanced activity in the implant location</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Stargardt's Macular Dystrophy</condition>
  <arm_group>
    <arm_group_label>50,000 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: MA09-hRPE Cellular therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MA09-hRPE</intervention_name>
    <description>MA09-hRPE: 50,000 cells</description>
    <arm_group_label>50,000 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female over 20 years of age.&#xD;
&#xD;
          -  Clinical diagnosis of advanced SMD.&#xD;
&#xD;
          -  The visual acuity of the eye to receive the transplant will be no better than hand&#xD;
             movement.&#xD;
&#xD;
          -  The visual acuity of the eye that is not to receive the transplant will be no better&#xD;
             than 24 (20/320) Early Treatment of Diabetic Retinopathy Study (ETDRS) letters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  History of myocardial infarction in previous 12 months.&#xD;
&#xD;
          -  History of diabetes mellitus.&#xD;
&#xD;
          -  Any immunodeficiency.&#xD;
&#xD;
          -  Any current immunosuppressive therapy other than intermittent or low dose cortico&#xD;
             steroids.&#xD;
&#xD;
          -  Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.&#xD;
&#xD;
          -  Current participation in any other clinical trial.&#xD;
&#xD;
          -  Participation within previous 6 months in any clinical trial of a drug by ocular or&#xD;
             systemic administration.&#xD;
&#xD;
          -  Any other sight-threatening ocular disease.&#xD;
&#xD;
          -  Any chronic ocular medications. Any history of retinal vascular disease (compromised&#xD;
             blood-retinal barrier). Glaucoma. Uveitis or other intraocular inflammatory disease.&#xD;
             Significant lens opacities or other media opacity. Ocular lens removal within previous&#xD;
             3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonkyung Song, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Bundang Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Stargardt Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

